Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at evaluere den langsigtede sikkerhed af Inclacumab administreret til deltagere med seglcellesygdom

29. oktober 2026 opdateret af: Pfizer

Et åbent udvidelsesstudie for at evaluere den langsigtede sikkerhed af Inclacumab administreret til deltagere med seglcellesygdom, som har deltaget i et Inclacumab klinisk forsøg

This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.

All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

241

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Rio de Janeiro, Brasilien, 20211-030
        • Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
      • São Paulo, Brasilien, 08270-070
        • Casa de Saude Santa Marcelina
      • São Paulo, Brasilien, 01232-010
        • Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
      • São Paulo, Brasilien, 08270-120
        • CEPEC-Centro de Pesquisa Clinica
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilien, 41253-190
        • Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
    • Pernambuco
      • Recife, Pernambuco, Brasilien, 50070-460
        • Multihemo Servicos Medicos S/A
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
        • Hospital de Clínicas de Porto Alegre
    • São Paulo
      • Ribeirão Preto, São Paulo, Brasilien, 14051-140
        • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
      • São José do Rio Preto, São Paulo, Brasilien, 15090-000
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 080020
        • Clinica de la Costa Ltda.
    • Cesar Department
      • Valledupar, Cesar Department, Colombia, 200001
        • Sociedad de Oncología y hematología del Cesar
    • Alabama
      • Mobile, Alabama, Forenede Stater, 36604
        • University of South Alabama Children's and Women's Hospital
      • Mobile, Alabama, Forenede Stater, 36604
        • Strada Patient Care Center, Pediatric Hematology
      • Mobile, Alabama, Forenede Stater, 36606
        • South Alabama Medical Science Foundation
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72202
        • Arkansas Children's Hospital
    • California
      • Orange, California, Forenede Stater, 92868
        • UC Irvine Medical Center
    • Connecticut
      • Farmington, Connecticut, Forenede Stater, 06030
        • UConn-Neag Comprehensive Cancer Center
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • University of Illinois Hospital and Health Sciences System (UI Health)
      • Chicago, Illinois, Forenede Stater, 60612
        • University of Illinois at Chicago (UIC) Clinical Research Center
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Forenede Stater, 02215
        • Dana-Farber Cancer Institute IDS Pharmacy
      • Boston, Massachusetts, Forenede Stater, 02115
        • Brigham And Woman's Hospital
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • University of Michigan Hospitals - Michigan Medicine
    • New York
      • The Bronx, New York, Forenede Stater, 10461
        • Jacobi Medical Center
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27705
        • Duke University Medical Center
      • Durham, North Carolina, Forenede Stater, 27710
        • DUMC Investigational Drug Services Pharmacy
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • McGovern Medical School at UTHealth
      • Houston, Texas, Forenede Stater, 77030
        • UT Physicians Comprehensive Sickle Cell Center Houston
      • Houston, Texas, Forenede Stater, 77030
        • UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital
      • Eldoret, Kenya, 30100
        • International Cancer Institute
      • Nairobi, Kenya, 00100
        • Gertrude's Children's Hospital
      • Nairobi, Kenya, 00100
        • Kenya Medical Research Institute - Centre for Respiratory Disease Research
      • Nairobi, Kenya, 00200
        • Strathmore University CREATES
    • Siaya County
      • Kisumu, Siaya County, Kenya, 40600
        • KEMRI/CRDR Siaya Clinical Research Annex
    • Beirut
      • Hamra, Beirut, Libanon
        • American University of Beirut Medical Center
    • North Lebanon
      • Tripoli, North Lebanon, Libanon
        • Nini Hospital
      • Enugu, Nigeria, 460000
        • University of Nigeria Teaching Hospital
      • Kaduna, Nigeria, 800212
        • Barau Dikko Teaching Hospital/Kaduna State University
      • Kano, Nigeria, 700223
        • Aminu Kano Teaching Hospital
      • Lagos, Nigeria, 100254
        • Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
    • Cross River State
      • Calabar, Cross River State, Nigeria, 540242
        • University of Calabar Teaching Hospital
    • Federal Capital Territory
      • Abuja, Federal Capital Territory, Nigeria, 900211
        • National Hospital Abuja
      • Gwagwalada, Federal Capital Territory, Nigeria, 902101
        • University of Abuja Teaching Hospital
    • Kaduna State
      • Zaria, Kaduna State, Nigeria, 810105
        • Ahmadu Bello University Teaching Hospital
      • Muscat, Oman, 123
        • Sultan Qaboos University Hospital
    • Southern
      • Jizan, Southern, Saudi Arabien, 82943
        • Prince Mohammed bin Nasser Hospital
      • Dar es Salaam, Tanzania, 11101
        • National Institute for Medical Research (NIMR)
      • Adana, Tyrkiet (Türkiye), 01130
        • Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
      • Adana, Tyrkiet (Türkiye), 01250
        • Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
      • Ankara, Tyrkiet (Türkiye), 06430
        • Hacettepe University Ihsan Dogramaci Children Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Participants who meet all the following criteria will be eligible for study enrollment:

  1. Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.

  2. Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.

  3. Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.

    Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.

  4. If sexually active, female participants of childbearing potential must consistently use highly effective methods of contraception consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.

  5. Participant has provided written informed consent/assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.

Exclusion Criteria:

Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:

  1. Female participant who is breastfeeding or pregnant.
  2. Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
  3. Participant withdrew consent from the originating inclacumab clinical study.
  4. Participant was lost to follow-up from the originating inclacumab clinical study.
  5. Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Inclacumab 30 mg/kg

Inclacumab 30 mg/kg administered intravenously (IV)

Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Tidsramme: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs.

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Annualized Rate of Vaso-occlusive Crises (VOCs)
Tidsramme: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
Tidsramme: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for >= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Number of Inpatient Hospitalization Days for a VOC
Tidsramme: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of SCD-related Urgent Care Visits
Tidsramme: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
Tidsramme: From first dose of study treatment (Day 1) up to Week 48

The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure.

From first dose of study treatment (Day 1) up to Week 48
Annualized Rate of Complicated VOCs
Tidsramme: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of Red Blood Cell (RBC) Transfusions
Tidsramme: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. marts 2022

Primær færdiggørelse (Faktiske)

7. november 2025

Studieafslutning (Faktiske)

7. november 2025

Datoer for studieregistrering

Først indsendt

29. marts 2022

Først indsendt, der opfyldte QC-kriterier

21. april 2022

Først opslået (Faktiske)

27. april 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • GBT2104-133
  • 2020-005289-32 (EudraCT nummer)
  • C5361003 (Anden identifikator: Alias Study Number)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .